Literature DB >> 1904115

Pharmacological study of TA-0910, a new thyrotropin-releasing hormone (TRH) analog (III): Inhibition of pentobarbital anesthesia.

M Yamamura1, K Kinoshita, H Nakagawa, R Ishida.   

Abstract

Sites and mechanisms of the antagonistic action of TA-0910, a new thyrotropin-releasing hormone (TRH) analog, on pentobarbital anesthesia were studied in rats. Intravenous administration of TA-0910 dose-dependently shortened the duration of pentobarbital anesthesia at 30 micrograms/kg or more. The anti-anesthetic action of TA-0910 after intracerebral injection was in the following order of effectiveness: the posterior lateral hypothalamic area greater than midbrain reticular formation greater than raphe nuclei = locus ceruleus greater than anterior lateral hypothalamic area = ventral globus pallidus = hippocampus. TA-0910 injected into the nucleus accumbens, medial septal nucleus, parietal cortex or striatum had no effect, even at high doses. The anti-anesthetic action of TA-0910 (0.1 mg/kg, i.v.) was inhibited by a low dose of scopolamine or mecamylamine and by a high dose of haloperidol, phenoxybenzamine or metergoline. However, physostigmine and oxotremorine showed no anti-anesthetic action alone or in combination with TA-0910 (0.01 mg/kg, i.v.). Pentobarbital anesthesia was not inhibited by carbachol injected into various sites of the brain. These results suggest that the inhibitory effect of TA-0910 on pentobarbital anesthesia is mainly produced by activation of the posterior lateral hypothalamic area and the midbrain reticular formation, and that the involvements of not only acetylcholine but also other neurotransmitters such as dopamine, serotonin, and noradrenaline should be examined for their anti-anesthetic action.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1904115     DOI: 10.1254/jjp.55.69

Source DB:  PubMed          Journal:  Jpn J Pharmacol        ISSN: 0021-5198


  4 in total

1.  Discovery of a low affinity thyrotropin-releasing hormone (TRH)-like peptide that exhibits potent inhibition of scopolamine-induced memory impairment in mice.

Authors:  Chhuttan L Meena; Shubdha Ingole; Satyendra Rajpoot; Avinash Thakur; Prajwal P Nandeker; Abhay T Sangamwar; Shyam S Sharma; Rahul Jain
Journal:  RSC Adv       Date:  2015-06-23       Impact factor: 3.361

Review 2.  The Thyrotropin-Releasing Hormone-Degrading Ectoenzyme, a Therapeutic Target?

Authors:  Jean-Louis Charli; Adair Rodríguez-Rodríguez; Karina Hernández-Ortega; Antonieta Cote-Vélez; Rosa María Uribe; Lorraine Jaimes-Hoy; Patricia Joseph-Bravo
Journal:  Front Pharmacol       Date:  2020-05-08       Impact factor: 5.810

3.  Taltirelin is a superagonist at the human thyrotropin-releasing hormone receptor.

Authors:  Nanthakumar Thirunarayanan; Bruce M Raaka; Marvin C Gershengorn
Journal:  Front Endocrinol (Lausanne)       Date:  2012-10-09       Impact factor: 5.555

4.  Differential activating effects of thyrotropin-releasing hormone and its analog taltirelin on motor output to the tongue musculature in vivo.

Authors:  Wen-Ying Liu; Hattie Liu; Jasmin Aggarwal; Zhi-Li Huang; Richard L Horner
Journal:  Sleep       Date:  2020-09-14       Impact factor: 5.849

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.